Multipurpose Prevention Technologies (MPTs) are an innovative class of products that deliver varied combinations of HIV prevention, other STI prevention, and contraception and will improve the lives of women and families worldwide.
This database includes MPT products that are currently funded and in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.
Click on the tables for MPT products in the development pipeline, listed by:
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
MPT in Development
Preclinical – Advanced (Pre2)
Delivery Route & Method:
Film - Vaginal
Mechanism of Action:
Short-term (on-demand) protective film that dissolves on contact with vaginal fluids to deliver combination antiviral compounds
Inst. for Research & Innovation in Health (i3S), U. of Porto
Foundation for Science and Technology, Portugal
Grant Project UID/BIM/04293/2019
European Regional Development Fund (ERDF) through COMPETE 2020 Program; Gilead Portugal
Description: This product introduces a new vaginal delivery system comprising the incorporation of tenofovir (TFV) and efavirenz (EFV)-loaded poly(lactic-co-glycolic acid) nanoparticles (NPs) into a polymeric film base (TFV/EFV NPs-in-film). TFV/EFV NPs-in-film was tested for its ability to deliver incorporated drugs. The delivery system provided enhanced genital distribution of drugs over 24 hours in mice, allowing higher genital concentrations of both drugs, namely as compared to their delivery in a liquid vehicle. Levels of EFV were also enhanced as compared to a film containing the drug directly dispersed in the film polymeric matrix. TFV/EFV NPs-in-film were further shown to be safe upon daily vaginal delivery for 14 -days to mice.
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.